| 000 | 01678 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517012330.0 | ||
| 264 | 0 | _c20151221 | |
| 008 | 201512s 0 0 eng d | ||
| 022 | _a1440-1681 | ||
| 024 | 7 |
_a10.1111/1440-1681.12362 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKilic, Ulkan | |
| 245 | 0 | 0 |
_aEfficacy of statins on sirtuin 1 and endothelial nitric oxide synthase expression: the role of sirtuin 1 gene variants in human coronary atherosclerosis. _h[electronic resource] |
| 260 |
_bClinical and experimental pharmacology & physiology _cApr 2015 |
||
| 300 |
_a321-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntioxidants _xtherapeutic use |
| 650 | 0 | 4 |
_aAtorvastatin _xtherapeutic use |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aCoronary Artery Disease _xdiagnosis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Frequency |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNitric Oxide Synthase Type III _xmetabolism |
| 650 | 0 | 4 |
_aOxidative Stress _xdrug effects |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 |
_aRosuvastatin Calcium _xtherapeutic use |
| 650 | 0 | 4 |
_aSirtuin 1 _xgenetics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGok, Ozlem | |
| 700 | 1 | _aElibol-Can, Birsen | |
| 700 | 1 | _aUysal, Omer | |
| 700 | 1 | _aBacaksiz, Ahmet | |
| 773 | 0 |
_tClinical and experimental pharmacology & physiology _gvol. 42 _gno. 4 _gp. 321-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/1440-1681.12362 _zAvailable from publisher's website |
| 999 |
_c24528355 _d24528355 |
||